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The aim of this study was to utilize molecu-
lar biology techniques to develop novel prog-
nostic methods for the management of solid
tumors. Squamous cell carcinomas of the head
and neck region and the uterine cervix have
served as model diseases for this purpose.
In the early stages of this study we devel-
oped a sensitive non-quantitative assay for de-
tecting occult epithelial cells in the circula-
tion of patients with cancer of the uterine cer-
vix, based on detection of squamous cell car-
cinoma antigen mRNA in peripheral blood.
With this technique we were able to detect
circulating cells in 6 out of 15 patients and
in two pregnant women at term. The low level
of target template in the blood samples, how-
ever, resulted in uncontrolled variability and
we turned the focus to developing accurate
techniques for quantification of gene expres-
sion in microscopic tissue sections. This led
to the development of an RT-PCR based tech-
nique for accurate quantification of the rela-
tive levels of the highly homologous SCCA1
and SCCA2 mRNAs occurring in biopsy
specimens of tumor tissue and normal epi-
thelium.
The relative levels of SCCA1 and SCCA2
mRNA in squamous cell tumors of the head
and neck region was demonstrated to corre-
late with tumor types displaying an aggres-
sive behavior as well as with the recurrence
free survival of the patients. The consistent
but subtle variations in the relative levels of
the SCCA genes were beyond the quantita-
tive accuracy of the most commonly used tech-
Abstract
niques for mRNA quantification. Our results
suggest that the ratio of SCCA2 to SCCA1
mRNA is a potential prognostic molecular
marker in head and neck cancer. As the num-
ber of patient samples with available follow
up data was limited in our study, the clinical
applicability of this novel marker remains to
be verified.
A mathematical algorithm was developed
in order to estimate the degree of variation
caused by stochastic factors in techniques
striving to quantify molecules in highly di-
luted solutions. The algorithm was tested
empirically using a highly optimized com-
petitive RT-PCR based assay to quantify rela-
tive levels of rare mRNAs at different sensi-
tivity levels. We were able to show that sam-
pling variation accounts for a major part of
the inaccuracy associated with highly sensi-
tive amplification and detection techniques.
In conclusion, we have been able to show
that highly accurate amplification based
mRNA quantification can be achieved by
comparing the levels of closely related tran-
scripts to each other. This concept was dem-
onstrated using a competitive RT-PCR sys-
tem with end-point detection. The technique
as such is unlikely to be directly applied as a
tool for mRNA based grading in the future
due to the relatively complicated methodol-
ogy. The concept of relative quantification of
closely related mRNA:s is however readily
applicable to a real-time PCR setup as well as
to other amplification and detection technolo-
gies.
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1. Introduction
In the process of carcinogenesis, accumula-
tion of multiple successive genetic alterations
eventually lead to the development of malig-
nant cells lacking normal mechanisms of cel-
lular control. In a healthy individual, a so-
phisticated surveillance system that repairs
potential carcinogenic mutations or alterna-
tively destines affected cells for apoptosis pre-
vents accumulation of successive carcinogenic
mutations in the same cell. Mutations that
target some part of this surveillance system,
thereby partly inactivating it, can however,
result in an accelerated rate of uncorrected
mutations, and subsequently to the develop-
ment of cancer [Fearon, 1990]. Such muta-
tions affect one of two major cellular func-
tions, namely the control of cell proliferation
or DNA proofreading and repair. In addition
there are a vast amount of genes involved in
normal physiologic processes that in a malig-
nant environment can supply tumors with
beneficial properties. Expression of genes in-
volved in angio- and lymphangiogenesis, cel-
lular adhesion, proteolytic degradation and
defense against immunological surveillance
provides subsets of malignant cells or cell
clones with a selection advantage during the
process of carcinogenesis. The accumulation
of a pattern of expressed genes that favor the
tumors potential for expansion, invasion and
metastatic spread eventually leads to an ag-
gressive behavior of the tumor. The expres-
sion of such genes and the resulting expres-
sion profiles of malignant cells provides the
targets for molecular characterization and clas-
sification of cancer.
At present, pathological diagnosis and clas-
sification of human neoplasia is based on rec-
ognition of histological features, with im-
munophenotyping and other molecular tech-
niques serving as ancillary methods. A com-
bination of pathological classification and
clinical criteria are used to distinguish prog-
nostically distinct classes and subclasses of
tumors in clinical settings [Alizadeh, 2001].
Due to the variation in the clinical behavior
of cancers within the currently accepted clas-
sifications, predictions of response to treat-
ment and clinical outcome are in many cases
inaccurate on the individual level. The dis-
covery of new molecular markers for classifi-
cation of malignant disease has been acceler-
ated by the development of DNA microarray
technology. Array generated expression pro-
files have been successfully used to define
novel cellular pathways and biologically-dis-
tinguishable tumor sub-categories [Alon,
1999; Ross, 2000; Perou, 2000; Bittner,
2000; Hedenfalk, 2001]. The vast amount of
expression data produced by microarray tech-
niques enables development of new clinical
test for monitoring genes involved in the con-
trol of specific cellular functions. Novel
mRNA expression based tests are likely to be
integrated with already established techniques
to enable a novel classification of human ma-
lignancies in order to guide specific treatment
of individual patients.
We have developed techniques to measure
the mRNA expression of the serum tumor
marker squamous cell carcinoma antigen genes
SCCA1 and SCCA2, and studied the expres-
sion of these genes in squamous cell carcino-
mas of the head and neck region and in the
uterine cervix. Both cancer forms evolve from
mucosal squamous epithelial cells, but result
in widely different disease patterns and out-
come. In head and neck cancer a high mortal-
Review of the literature
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2.1 Overview
An estimated 860.000 new cases of head and
neck cancer was diagnosed in 1990 [Parkin,
1999] making it the seventh most common
form of cancer in the world. Of these new cases
634.000 were diagnosed in men and 228.000
in women. Head and neck cancer includes
squamous cell carcinomas arising from the
mucous membranes lining the upper aerodi-
gestive tract. This area comprises the lip, the
oral and nasal cavities, the paranasal sinuses,
the larynx, and pharynx [Clayman, 1996].
(fig. 1) Carcinomas of the salivary glands and
nasopharynx are considered distinct etiologic
groups of head and neck cancer. Other tumors
of this region including skin, brain, ocular
and infrequent sarcomas and lymphomas are
considered as separate entities [Vokes, 1993].
Patients with stage I or II disease generally
undergo either surgery or radiotherapy with
curative intent. Over 80% of patients present-
ing with stage I disease and over 60% of those
with stage II will be cured [Vokes, 1993].
Patients presenting with stage III–IV local
or regionally advanced disease will typically
receive sequential radiotherapy and extensive
radical surgery including a neck dissection.
Fewer than 40% of these patients achieve 2-
year disease free survival and different com-
binations of chemotherapy with the standard
regimens are used in order to achieve organ
preservation and prolonged survival in speci-
fied settings [Clayman, 1996]. Mortality in
head and neck cancer is mainly due to pri-
mary treatment failure or to locoregional re-
current disease in patients initially reaching
remission [Vokes, 1993].
2.2 Etiology
Squamous cell carcinoma of the head and neck
is a heterogeneous disease with distinct pat-
terns of presentation and behavior. The ma-
jority of head and neck cancers are associated
with heavy consumption of tobacco and alco-
hol [Vokes, 1993]. Many of the patients
present with multiple foci of cancerous or
precancerous cells, so-called field canceriza-
tion [Slaughter, 1953], throughout the up-
per aerodigestive tract. Molecular data has
provided evidence of the causal role of these
substances in the process of head and neck
carcinogenesis [Brennan, 1995]. A feature
typically affecting this group of patients is
second primary tumors which develop at an
annual rate of 4–7% of all head and neck can-
cer patients irrespectively of the result of the
primary treatment. These new and potentially
fatal cancers typically evolve in the anatomi-
cal regions of smoking-related carcinogenesis
and in the bladder. Two different types of vi-
ral infections have been linked to the etiol-
ogy of head and neck cancer. More than half
of the squamous cell carcinomas arising in the
oropharynx contain DNA of human papilloma
virus (HPV) [Gillison, 2000]. It is thought
that HPV-positive oropharyngeal tumors
ity rate combined with significant morbidity
caused by aggressive treatment protocols gen-
erates a need for new predictive techniques that
would aid clinicians in determining the opti-
mal treatment strategy for individual patients.
The disease pattern of cervical cancer differs
significantly from that of head and neck can-
cer as cytological screening has led to early
diagnosis in developed countries and the ma-
jority of cases can be cured by radical therapy.
The need for prognostic indicators in this type
of cancer is restricted to the subgroup of pa-
tients in which cellular atypia of undetermined
significance is found in cytological screening.
2. Head and neck cancer
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comprise a distinct disease entity initially
caused at least in part by an HPV infection.
Nasopharyngeal carcinoma represents a dis-
tinct entity of head and neck cancers which
has been strongly linked to Epstein-Barr vi-
rus (EBV) infection [Chien, 2001; Lo, 1999;
Shotelersuk, 2000]. This type of head and
neck cancer, often presenting with poorly dif-
ferentiated or undifferentiated histology, is
endemic in northern Africa and many Asian
populations and differs from squamous cell
carcinoma of other sites in the head and neck.
In this type of disease the rates of local con-
trol are typically high but the development
of distant metastases is common and often
lethal.
2.3 Molecular basis of oncogenesis
Chromosomal alterations linked to head and
neck cancer have suggested specific genetic
regions to be involved in the early develop-
ment of this type of cancer.
The most common genetic change is loss
of the chromosomal region 9p21 which is an
early event in the progression of these tumors.
Deletion of 9p21 results in loss of the Ink4a/
ARF locus and subsequently to inactivation
of the p16INK4a and ARF proteins. p16 and
ARF are both involved in a complex signal-
ing network regulating and interconnecting
the activities of RB protein and p53 [Sherr,
2001]. p16 is important in regulating the cell
Figure 1. Sagittal section of the upper aerodigestive tract. Squamous cell carcinoma of the head and neck
evolves from the epithelium lining the lip, the oral and nasal cavities, the paranasal sinuses, the larynx, and
the pharynx. (Adapted from Vokes EE et al. Head and neck cancer. NEJM 1993; 328: 184–94.)
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cycle through inhibition of cyclin dependent
kinase (CDK) [Kamb, 1994; Reed, 1996] and
keratinocytes in culture have been shown to
escape senescence as a result of lost p16 func-
tion [Papadimitrakopoulou, 1997; Munro,
1999]. p53 is mutated in more than 50% of
all human cancers [Sherr, 2001] and corre-
spondingly approximately half of all head and
neck cancers contain a mutation of the p53
gene. The loss of p53 function results in a
progression from preinvasive to invasive le-
sions and increases the likelihood of further
genetic progression.[Boyle, 1993; Hartwell,
1994; Koch, 1996]. In about one third of the
tumors the oncogene cyclin D1 is amplified
resulting in constitutive activation of cell cycle
progression. Cyclin D1 amplification has been
associated with invasive disease [Berenson,
1989; Callender, 1994; Jares, 1994]. On the
contrary no tumor suppressor genes have been
directly linked to the chromosomal regions
most commonly lost [Nawroz, 1994; Ah-See,
1994].
2.4 Treatment strategies
New treatment strategies have succeeded in
improving quality of life through conserva-
tion of organ function, such as swallowing and
speech as well as minimizing cosmetic handi-
cap. These strategies include surgical tech-
niques for preservation of laryngeal function,
selective neck dissection and reconstruction of
tissue defects. Hyperfractionation of radio-
therapy allowing escalation of the total dose
by minimizing damage to normal cells and
accelerated fractionation protocols shortening
the duration of therapy and thereby reducing
the potential for tumor repopulation between
fractions, have been tested in phase III clini-
cal trials. These have documented a 10–15%
improvement in local control in stage II–IV
patients, however, without a significant in-
crease in overall survival [Forastiere, 2001].
Induction chemotherapy followed by radio-
therapy has become a standard treatment in
advanced cancer of the larynx and has resulted
in preservation of a functional larynx in about
half of the cases [The Department of Veterans
Affairs Laryngeal Study Group, 1991;
Lefebvre, 1996]. Concurrent chemotherapy
and radiotherapy has been shown to be an ef-
fective alternative for selected patients with
oropharyngeal, nasopharyngeal and locally ad-
vanced unresectable tumors of various origins.
The role of adjuvant chemotherapy for high
risk patients initially reaching remission is cur-
rently under evaluation [Forastiere, 2001].
Promising novel therapies targeted specifically
to patients with head and neck cancers include
the epidermal growth factor-receptor antago-
nists CDK inhibitors and replication compe-
tent adenoviruses. Monoclonal antibodies
against epidermal growth factor receptor,
which is overexpressed in over 90% of head
and neck cancers, have been shown to inhibit
cell proliferation mediated through autocrine
and paracrine pathways by blocking ligand
binding [Mendelsohn, 1997; Grandis, 1998].
Small molecule drugs based on this finding
have reached phase I and II trials. Replication-
competent adenoviruses have been developed
that selectively replicate in and cause lysis of
p53 deficient cells [Heise, 1997; Heise, 1999].
For the time being aggressive surgical resec-
tion remains the cornerstone of therapy in head
and neck cancer [Forastiere, 2001].
2.5 Pathological classification
Staging of head and neck cancer has changed
very little over the passed decade [Forastiere,
2001; Vokes, 1993]. Traditional staging sys-
tems including TNM classification deter-
mined by clinical examination, imaging pro-
cedures and surgical findings, histological
grade and clinical patient characteristics only
weakly predict the outcome of treated indi-
viduals [Forastiere, 2001]. A variety of serum
tumor markers including SCCA, CEA, CA
19-9, sialic acid and ferritin have been evalu-
ated for detecting occult malignancy and
monitoring treatment of head and neck can-
cer. None of these have however reached wide-
spread clinical use due to lack of sensitivity
and specificity [Rassekh, 1994]. Serial post-
operative measurements of squamous cell car-
cinoma antigen (SCCA) is being used in some
13
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centers for early detection of recurrent dis-
ease [Snyderman, 1995; Lara, 1995]. Several
other parameters have been proposed includ-
ing new imaging techniques and identifica-
tion of sentinel nodes by lymphoscintigraphy
[Alex, 2000; Koch, 1998]. Genetic changes
in the form of loss of heterozygosity [Rosin,
2000], allelic imbalance [Partridge, 2000]
and nuclear DNA ploidy [Sudbo, 2001] have
been used to characterize early head and neck
cancer lesions. Mutations in the p53 gene have
been used to detect residual cancer cells in
tissue margins at the periphery of the tumor
[Brennan, 1995]. Detection of occult epithe-
lial cells in lymph nodes has been accom-
plished by detecting p53 mutations [Par-
tridge, 2000] as well as tissue specific expres-
sion of MET [Cortesina, 2000] and SCCA
[Hamakawa, 1999] genes. Molecular tech-
niques have also been used to determine the
relation between a primary tumor and subse-
quent lesions [Leong, 1998; Califano, 1999]
in order to aid clinicians in determining
whether to treat a second primary lesion ag-
gressively or to settle for palliative treatment
in the case of distant metastatic disease. De-
spite that many of the new molecular tech-
niques for characterization and classification
of head and neck cancer have been shown to
provide predictive information on the risk of
disease recurrence, none so far have reached
widespread clinical practice.
3. Cancer of the uterine cervix
3.1 Overview
Cervical cancer was diagnosed in 371.000
new cases in 1990 [Parkin, 1999]. It is the
second most common cancer in women
worldwide. Almost 80% of the cases occur
in developing countries where cervical can-
cer accounts for 15% of cancers in women.
The incidence and mortality in cervical can-
cer have decreased substantially in most de-
veloped countries due to long-standing Pa-
panicolaou (Pap) screening programs [Parkin,
2001]. Approximately 80% of cervical can-
cers are squamous cell carcinomas, while 20%
are mixed, adenomatous or metastatic to the
cervix [DiSaia, 1997]. The most important
cause of cervical cancer is human papilloma
virus (HPV) infection [zur Hausen, 1976;
Boshart, 1984], and HPV DNA can be found
in the vast majority of tumors and intraepi-
thelial lesions [Cannistra, 1996]. When de-
tected at an early stage, cervical cancer is
largely a curable disease. Microinvasive stage
IA1 disease has less than a 1% risk of lymph
node spread and can thus be effectively
treated by hysterectomy or cervical coniza-
tion, yielding nearly 100% cure rates [Na-
tional Institutes of Health Consensus Devel-
opment Conference statement on cervical
cancer., 1997]. Early forms of invasive dis-
ease (stage IA2–IIA) are treated by surgery
alone or in combination with external beam
or intracavitary radiotherapy. Five-year dis-
ease free survival rates of 80–90% have been
reported for this group of patients. Locally
advanced (stage IIB, III and IVA) disease has
been mainly treated with radiotherapy result-
ing in survival rates of 65%, 40% and less
than 20% respectively [Cannistra, 1996].
(fig. 2) The combination of chemo- and ra-
diotherapy as a standard regimen for treat-
ment has significantly improved survival
rates in these groups [Whitney, 1999; Mor-
ris, 1999; Rose, 1999; Keys, 1999; Peters,
2000], however long-term follow up data is
still lacking. Adenocarcinoma has a poorer
prognosis at every stage compared to squa-
mous cell carcinoma, and the prognosis of
adenosquamous cancer is poorer still
[Canavan, 2000].
Jakob Stenman
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3.2 Etiology
The human papillomavirus (HPV) plays a
central role in the etiology of cervical can-
cers. More than 95% of these cancers have
been shown to harbor HPV DNA. [Bosch,
1995; Ngelangel, 1998; Chichareon, 1998;
Walboomers, 1999]. HPV is a double-
stranded DNA tumor virus ubiquitous in
higher vertebrates. Of the more than 100
characterized types of HPV capable of affect-
ing humans at least 25 infect the genital tract
[Janicek, 2001]. Low-risk varieties of HPV
are associated with viral condyloma or mild
dysplastic changes in the cervical epithelium
which rarely progress into invasive disease.
In contrast high-risk variants of HPV such
as types 16, 18, 31, 33 and 35 are often ob-
served in association with moderate to se-
vere dysplasia and carcinoma in situ as well
as in invasive cancer [Crum, 1984; Koutsky,
1992; Crum, 1985; Willett, 1989; Howley,
1991]. Other risk factors for cervical cancer
include smoking, immunosuppression,
young age at first intercourse, high number
of sexual partners, high parity and low so-
cioeconomic status [Cannistra, 1996;
Janicek, 2001]. Of these risk factors most
are linked to sexual behavior and an increased
risk of acquiring HPV. Smoking has consis-
tently been shown to be an independent risk
factor and even passive smoking has been
associated with an increased risk of specifi-
cally squamous cell carcinomas, but not with
adenocarcinomas or adenosquamous carcino-
mas [Brinton, 1986; Slattery, 1989]. HIV
infection is associated with a higher incidence
of cervical dysplasia, more multifocal lesions,
more rapid progression and higher recurrence
rates when compared with HIV-negative
women [Maiman, 1993; Klein, 1994]. HIV-
positive women with invasive cancer also
tend to present with advanced stage disease,
have resistance to therapy and a shortened
survival [Rellihan, 1990; Maiman, 1993].
There has however been no consistently docu-
mented rise in the incidence of invasive cer-
vical carcinomas in HIV-infected women
[Janicek, 2001].
3.3 Molecular basis of oncogenesis
The molecular basis for oncogenesis in the
majority of cervical cancers is explained by
the function of viral oncogenes E6 and E7
which are integral structures of the HPV-fam-
ily of viruses [Howley, 1991; Scheffner, 1991].
The gene product of E6 has been shown to
induce degradation of resident p53 protein
by binding to it [Werness, 1990; Scheffner,
1990]. Inactivation of p53 through either E6
binding or mutation is a central component
in the process of malignant transformation in
cervical cancer, and p53 has been shown to be
mutated in the minority of cervical cancers
not infected with HPV [Scheffner, 1991; Park,
1994]. E7 targets another closely related tu-
mor suppressor gene product, the retinoblas-
toma protein (pRb) by binding to it and
changing its phosphorylation state [Munger,
Figure 2. Algorithm for managing micro-invasive or invasive cervical cancer. (Adapted from Cannistra SA
and Niloff JM. Cancer of the uterine cervix. NEJM 1996; 334: 1030–8.)
Histologic disease Stage Treatment
Microinvasive disease IA Simple hysterectomy or careful observation
after adequate cone biopsy
Invasive disease IB or IIA Radical hysterectomy with pelvic-node disection
or external beam and intracavitary radiotherapy
IIB, III, or IVA Pelvic radiotherapy
IVB Chemotherapy with or without pelvic radiotherapy
15
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1989; Dyson, 1989]. Phosphorylation of pRb
disrupts its ability to suppress E2F transcrip-
tion factor and cell cycle progression into S-
phase is accelerated [Sherr, 2001]. HPV types
are stratified into, low- intermediate- and
high-risk categories based on their association
with high grade and invasive cervical lesions
[Syrjanen, 1988; Lorincz, 1992]. The high-
risk HPV types exhibit greater inactivation
of p53 and RB and a single amino acid differ-
ence has been shown to be critical for the dif-
ferent binding affinities for RB [Heck, 1992].
Certain loci of the human leukocyte antigens
(HLA) or major histocompatibility antigens
has been associated with specific types of HPV
in cervical cancers [Ellis, 1995; Allen, 1996].
Interactions of HPV with specific histocom-
patibility antigens might explain the differ-
ences in patterns of progression to invasive
disease in patients infected with the same
HPV type [Janicek, 2001].
3.4 Screening and treatment strategies
The widespread screening programs based on
Pap-smear cytology have reduced the inci-
dence and mortality from cervical cancer by
up to 60–80% in some developed countries
[Miller, 2000]. The age limits for initiation
and discontinuation of screening as well as the
screening frequency varies somewhat in dif-
ferent countries [Sawaya, 2001]. New screen-
ing techniques include liquid-based cytology
collection and analysis [Payne, 2000]. Com-
puterized analysis of Pap-smears [Colgan,
1995; Ashfaq, 1995; Brown, 1999] and HPV
testing [ALTS Group, 2000; Schiffman, 2000;
Solomon, 2001]. Ablative treatment for
microinvasive and early invasive forms of cer-
vical cancer is associated with excellent results
and has changed little over the last decades.
Combination of chemotherapy to radiotherapy
and surgery in locally advanced and high-risk
early stage disease seems to bring about an
increase in overall survival in these patient
groups. Novel preventive treatment strategies
such as development of vaccines against the
most prevalent high-risk HPV types could
theoretically prevent more than 300.000 cer-
vical cancer cases per year worldwide [zur
Hausen, 2001]. Presently a number of phar-
maceutical companies as well as research labo-
ratories are engaged in preclinical and clinical
trials of vaccines against high-risk HPV
strains. Most approaches are based on virus-
like particles (VLP) representing structural
proteins L1 or L1 and L2 of papillomaviruses
[Zhou, 1991; Zhou, 1992; Zhang, 2000]. The
first published report after conclusion of phase
I immunogenicity and safety trials on a
HPV16 L1 VLP vaccine [Harro, 2001; zur
Hausen, 2001] has shown very promising re-
sults being highly immunogenic and well tol-
erated.
3.5 Pathological classification
The Bethesda classification is the most widely
used cytologic classification of Pap-smears
[Shingleton, 1995; 1989; Kurman; 1991].
Abnormal findings are categorized into low
grade squamous intraepithelial lesions (LGSIL),
high grade intraepithelial lesions (HGSIL) and
squamous cells of undetermined significance
(ASCUS). Corresponding classifications also
exist for glandular lesions. When cytologic ab-
normalities are reported, colposcopy is per-
formed to permit visualization and biopsy of
the lesion. Biopsy findings are classified as cer-
vical intraepithelial neoplasia (CIN) I, II or III
corresponding to mild, moderate and severe
dysplasia or carcinoma in situ.The staging sys-
tem for cervical cancer is based on clinical cri-
teria according to the international federation
of gynecology and obstetrics staging system
(FIGO) [Creasman, 1995]. Serum marker squa-
mous cell carcinoma antigen (SCCA) has been
widely used for monitoring patients treated for
advanced cervical squamous cell cancer for early
detection of relapses [Brioschi, 1991] and HPV
typing of cytology specimen has been shown
to provide additional prognostic information
to samples classified as ASCUS [Manos, 1999;
Solomon, 2001; Hildesheim, 2001]. These
groups of patients would benefit from addi-
tional prognostic parameters to alleviate de-
termination of optimal follow up and treat-
ment strategies.
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4. Squamous cell carcinoma antigen
4.1 Overview
Squamous cell carcinoma antigen (SCCA) is
the major component of the TA-4 antigen com-
plex originally isolated from metastatic cervi-
cal squamous cell carcinoma tissue [Kato,
1977]. The 14 isoforms of the protein ranging
from 42 to 48 kDa were initially grouped into
a neutral (pI 6.3–6.6) and an acidic (pI 5.9–
6.2) fraction on the basis of their isoelectric
points [Kato, 1984]. The neutral and acidic
isoforms of SCCA have been shown to be coded
by separate genes and have been named SCCA1
and SCCA2 respectively [Schneider, 1995].
Both forms of SCCA are expressed in normal
and malignant squamous epithelium [Crom-
bach, 1989; Cataltepe, 2000] but the increased
serum levels of SCCA observed in cancer pa-
tients is thought to be mainly attributed to
increased levels of SCCA2 [Kato, 1984]. The
commercially available immunoassay for SCCA
(IMx SCC kit, Abbott Laboratories Inc.,
Abbott Park, IL) does not discriminate between
the SCCA isoforms but has reached widespread
clinical use as a serum marker in the manage-
ment of squamous cell carcinoma of the uter-
ine cervix and to some extent in head and neck
cancer. The detection limit of this microparti-
cle enzyme immunoassay (MEIA) based
method is 0.3 µg/l and the upper reference
limit for healthy subjects is 2.5 µg/l. It has
been mainly used for monitoring response to
therapy and for early detection of relapses
[Fuith, 1988; Senekjian, 1987]. The pretreat-
ment levels of SCCA have been shown to cor-
relate mainly with tumor size [Brioschi, 1991]
and the prognostic value of pretreatment mea-
surements is being debated [Duk, 1996;
Bolger, 1997].
4.2 Genes and proteins
The SCCA1 and SCCA2 genes are tandemly
arrayed on chromosome 18q21.3 [Schneider,
1995; Kuwano, 1995]. (fig. 3) The SCCA
genes belong to the ovalbumin family of serine
proteinase inhibitors (serpins) [Suminami,
1991] and they are flanked by two other
closely related serpins, plasminogen activa-
tor inhibitor type 2 (PAI2) and maspin. The
exon sequences of the SCCA genes display
98% homology, whereas the predicted amino
acid sequences are 92% homologous. Recom-
binant SCCA2 functions as a classical serpin
inhibitor of chymotrypsin-like proteinases
human neutrophil cathepsin G (cat G) and
human mast cell chymase (HMC) [Schick,
1997]. SCCA1 on the other hand, inhibits
papain-like cysteine proteinase such as cathe-
psin K, L and S but not common serine pro-
teinases [Schick, 1998]. (table 1) The major-
ity of amino acids that differ between SCCA1
and SCCA2 reside in the exposed portion of
the reactive site loop (RSL). Site-directed mu-
tagenesis directed at either the hinge or the
variable region of the RSL abolished its in-
hibitory activity and it has been suggested
that it is the altered sequence and flexibility
of the RSL itself that enables cross-class inhi-
bition of cysteine proteinases by SCCA1
[Schick, 1998].
4.3 Expression and distribution
RNA transcripts of SCCA1 and SCCA2 have
been detected in human lung, tonsil, thy-
mus, lymph node placenta, prostate and tes-
tis using RT-PCR [Cataltepe, 2000]. Using
immunohistochemistry with discriminatory
monoclonal antibodies for the SCCA1 and
SCCA2 isoforms [Cataltepe, 2000] these
proteins were shown to be co-localized to
the skin, esophagus, tonsil, tongue, thymus,
trachea, bronchi, bronchiole, vagina and
uterine cervix [Cataltepe, 2000]. Non-dis-
criminatory in situ hybridization experi-
ments have localized SCCA mRNA to the
basal and parabasal layers of normal squa-
17
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Figure 3. Genomic map of SCCA1 and SCCA2 genes. (Adapted from Schneider SS et al. A serine proteinase
inhibitor locus at 18q21.3 contains a tandem duplication of the human squamous cell carcinoma antigen
gene. Proc Natl Acad Sci USA 1995; 92: 3147–51.)
Table 1. Inhibitory profiles of SCCA1 and SCCA2
Proteinase
(final concentration)
catG (42nM)
HMC (50 nM)
Chymotrypsin (400 nM)
Granzyme B (130 nM)
HNE (330 nM)
Plasmin (17 nM)
Proteinase 3 (35 nM)
PSA (140 nM)
Thrombin (19 nM)
Trypsin (450 nM)
u-PA (100 nM)
catB (23 nM)
catS (19 nM)
catL (4.3 nM)
catK (50 nM)
Papain (207 nM)
SCCA1
(µM)
0.48
0.48
33.0
20.0
33.0
0.48
0.48
18.0
2.0
33.0
2.0
2.0
1.0
0.086
0.7
0.36
SCCA1
Ratio
(I/E)
11
10
83
154
100
28
14
129
105
73
20
87
100
20
14
2
Inhibition
(%)
0
0
0
0
0
0
0
0
0
0
0
0
99
93
75
91
SCCA2
(µM)
0.4
0.4
22.0
13.0
22.0
0.4
0.4
14.0
2.0
22.0
2.0
2.0
ND
0.043
0.2
ND
SCCA2
Ratio
(I/E)
10
8
55
100
67
24
11
100
53
49
20
87
ND
10
4
ND
Inhibition
(%)
100
100
0
0
0
0
79
0
0
0
0
0
ND
0
0
ND
Inhibitory profiles of SCCA1 and SCCA2. (Modified from Schick C et al. Cross-class inhibition of the cystein proteinases
cathepsins K, L, and S by the serpin squamous cell carcinoma antigen 1: A kinetic analysis. Biochemistry 1998; 37:
5258–66, and Schick C et al. Squamous cell carcinoma antigen 2 is a novel serpin that inhibits the chymotrypsin-like
proteinases cathepsin G and mast cell chymase. J Biol Chem 1997; 272: 1849–55.)
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5. Techniques for measurement of mRNA-expression
5.1 Strategies for quantification of
mRNA expression in malignant cells
In order to characterize the expression of genes
critical for the behavior of tumors, patholo-
gists have traditionally relied on immunohis-
tochemistry in paraffin-embedded tissues.
Proteins being the effector molecules in most
cellular mechanisms, are a natural target for
endpoint evaluation of gene expression, and
there is no doubt that this will remain a cen-
tral technique in grading of tumors in the
foreseeable future. There are however, several
factors limiting the applicability of immu-
nologic techniques for specific purposes. Se-
cretion of proteins to extracellular compart-
ments, complexing by binding to inhibitors
or carrier molecules, and highly variable deg-
radation rates render quantitative analysis of
gene expression on the protein level relatively
mous epithelium, in dysplasia and in inva-
sive squamous cell carcinoma [Takeshima,
1992]. Although SCCA1 and SCCA2 are
detected in the cytoplasm of normal squa-
mous epithelial cells, neither serpin is de-
tected normally in serum. Expression of
SCCA-green fluorescent fusion protein and
confocal microscopy has been used to study
the release of SCCA1 and SCCA2 from squa-
mous carcinoma cells. In this study the
SCCA-fusion proteins were found exclusively
in the cytosol and were not associated with
nuclei, mitochondria, lysosomes, microtu-
bules, actin or the Golgi. Neither non-stimu-
lated nor stimulated squamous carcinoma
cells secreted SCCA into the medium sug-
gesting that the major site of SCCA1 and
SCCA2 inhibitory activity is within the cy-
tosol and that the elevated SCCA serum lev-
els of patients with squamous-cell carcino-
mas may be due to passive release into the
circulation [Uemura, 2000].
4.4 Pathophysiological role
The possible role of the serine proteinase in-
hibitors SCCA1 and SCCA2 in the develop-
ment of squamous epithelial malignancies is
currently unknown. SCCA2 has been sug-
gested to protect the epithelia of the skin
and lung against inflammatory degradation
by inhibiting leukocyte proteinases HMC
and cat G [Schick, 1997]. This theory is
strengthened by the earlier finding that in-
flammatory skin disorders such as psoriasis
and atopic dermatitis are associated with in-
creased serum levels of SCCA [Duk, 1989;
Campbell, 1990]. The role of the observed
cross-class inhibition of cystein proteinases
by SCCA1 has not been clarified. It has been
proposed that SCCA1 is involved in the con-
trol of normal and pathological proteolytic
events by inhibition of lysosomal enzymes
catK, -L, and -S, released from damaged epi-
thelial cells [Schick, 1998]. Tumour cells
transduced with the SCCA1 cDNA have been
shown to be more resistant to induced
apoptosis as compared to control cells in
vitro. These cells also formed larger tumors
than corresponding controls in nude mice
[Suminami, 2000]. Recombinant SCCA1 has
been shown to inhibit migration of NK-cells
in vitro. This inhibitory effect is lost by in-
troducing a single amino acid mutation to
the reactive site loop [Suminami, 2001].
Suppression of both SCCA proteins using an
antisense SCCA mRNA construct has re-
sulted in inhibition of tumor growth and
increased infiltration of natural killer cells
in vitro which may contribute to the escape
of squamous cell carcinoma cells from the
host immune system [Suminami, 2001].
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inaccurate. In addition, synthesis of discrimi-
natory antibodies for closely related proteins
while retaining sufficient binding affinity, can
in some cases be difficult or maybe even im-
possible. mRNA in contrast, is synthesized,
functions and is degraded intracellularly, and
can in this aspect be considered a potential
target for quantitative analyses of gene expres-
sion. Several different techniques enable dis-
crimination of mRNA transcripts on the ba-
sis of single nucleotide differences allowing
independent analysis of highly homologous
transcripts. Measurement of cellular content
of specific mRNA transcripts thus provides a
versatile method for accurate quantitative
analysis of gene expression levels.
Clinical tumor tissue samples generally
consist of mixtures of cell types including
tumor cells, several different cell types of the
normal surrounding tissue, inflammatory cells
as well as necrotic cells often in the center of
the tumor. In situ detection of mRNA en-
ables visualization of localized gene expres-
sion in a heterogeneous surrounding without
purification of malignant cells. Detection of
multiple transcripts, however, is limited in
an in situ format and low-abundance mRNA
species often require amplification procedures
commonly performed in homogeneous assays.
To enable measurement of tumor-derived
mRNA from heterogeneous samples in a ho-
mogeneous assay, tumor cells can be either
physically separated from the surrounding
cells or alternatively the analysis can be fo-
cused on tissue-specifically expressed genes.
Microdissection procedures [Kubo, 1995;
Emmert-Buck, 1996; Bonner, 1997; Simone,
1998] have been successfully used to clean
tissue samples from other than tumor tissues
and to specifically select tumor cells from a
heterogeneous surrounding in a tissue sample.
With laser assisted microdissection and RT-
PCR, amplified mRNA transcripts have been
detected even in single cells [Schutze, 1998].
Various immunologic techniques have been
utilized in an analogous manner to select tu-
mor cells or to disselect leukocytes in blood
and other body fluid samples. A method of
circumventing the need for purification of
tumor cells is to detect mRNA transcripts
displaying tissue- or cell-type-specific expres-
sion. This method was originally described
for detecting occult malignant cells in blood
[Smith, 1991] and analogous techniques have
later been applied to tissue samples. Co-varia-
tion in the expression of cell-type specific
genes has been used to normalize expression
profiles obtained from clinical tumor samples
with cDNA arrays [Ross, 2000].
5.2 mRNA detection techniques
5.2.1 Hybridization on solid supports and gene
expression profiling
The first widely used technique for quantifi-
cation of specific mRNAs was the northern blot
hybridization assay [Alwine, 1977], a modifi-
cation of the southern blot earlier described
for detecting specific sequences among DNA
fragments separated by gel electrophoresis
[Southern, 1975]. Northern blotting involves
size-fractionation of total RNA or mRNA
samples and transfer to a nylon or nitrocellu-
lose membrane where specific sequences can
be detected by hybridization with typically a
32P-labelled DNA or oligonucleotide probe. In
RNA dot blot hybridizations [Kafatos, 1979]
the size-fractionation step is omitted and the
target RNA is blotted directly onto a mem-
brane. While these early RNA detection tech-
niques allow simultaneous detection of a spe-
cific transcript in several samples with labelled
probes, the development of reverse dot blot
assays enabled detection of multiple sequence
targets in single labelled samples [Bugawan,
1991]. Subsequent automation and miniatur-
ization of the dot blot increased the number of
genes that could be studied in a single experi-
ment, as specific cDNAs were arrayed onto
membranes [Lennon, 1991].
Microarray or chip technology utilizing
glass as the solid support has dramatically
increased the number of genes that can be
studied simultaneously. In a typical experi-
ment mRNA isolated from a tissue sample or
a cell line is reverse transcribed and labelled
to generate a target that can be detected upon
Jakob Stenman
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hybridization to the microarray. Labelling of
the target can be done by incorporating la-
beled nucleotides during reverse transcription,
but many protocols require an amplification
step in order to produce sufficient amounts
of target template for the hybridization reac-
tion. High density oligonucleotide arrays de-
veloped at Affymetrix Inc. are manufactured
by in situ photolithographic synthesis of oli-
gonucleotide probes based on database se-
quence information. Hybridization events on
the array are monitored by laser confocal fluo-
rescent scanning in up to one million loca-
tions. [Fodor, 1991; Southern, 1992; Fodor,
1993; Pease, 1994]. Multiple independent
probes specific for different regions of the same
target template are used in order to increase
signal-to-noise ratio and enable quantification
of up to 40.000 target templates. The quan-
titative accuracy of commercially available
oligonucleotide arrays allows discrimination
of two-fold differences in expression levels
[Lipshutz, 1999]. cDNA microarrays [Schena,
1995; Shalon, 1996; Schena, 1996] are con-
structed by printing DNA probes on the solid
support using ink-jet technology. Two-color
fluorescence hybridization is used to quanti-
tatively analyse the relative expression levels
of maximally tens of thousands of genes in a
test sample in relation to those of a reference
sample (fig. 4). By measuring the ratio of dif-
ferently labelled targets in a mixture, inaccu-
racy due to variable hybridization kinetics is
minimized. The ink-jet technology has been
expanded to printing of oligonucleotides
which allows synthesis of probes based on
database sequence information. Generation of
this type of DNA microarrays in an academic
environment provides a cost effective alter-
native for gene expression profiling whereas
ready-to-use cDNA microarrays are also com-
mercially available.
An alternative method for analysis of gene
expression patterns is Serial Analysis of Gene
Expression (SAGE). [Velculescu, 1995] In this
technique mRNA is isolated from the source
and reverse transcribed. The cDNA molecules
are restriction endonuclease digested (anchor-
ing enzyme), ligated to one of two primer
specific linker sequences and reduced to 9 nt
sequence tags by a second cleavage with a type
IIS restriction nuclease (tagging enzyme). The
Figure 4. Gene expression analysis using cDNA microarrays. The total pool of mRNA from a test sample and
a reference sample is used to prepare fluorescently labelled cDNA by reverse transcription with fluorescently
labelled nucleotides. The two differently labelled cDNAs are mixed and hybridized on a cDNA microarray.
Each gene to study is represented as a distinct spot of DNA in the array. The relative abundance of specific
transcripts in the samples is reflected as the ratio of fluorescence measured in the respective spot. (Adapted
from Brown PO and Botstein D. Exploring the new world of the genome with DNA microarrays. Nature
Genetics 1999; 21, suppl.: 33–7.)
mRNA cDNA, greenfluorescence
mRNA cDNA, redfluorescence
Each spot on the array contains
cDNA or oligonucleotide
hybridization probes specific
for separate genes
Reference sample
Test sample
A mixture of equivalent
amounts labeled cDNA
from the test and reference
samples is applied to the
microarray
The ratio between green and
red fluorescence is measured
separately in each spot
An increse in the relative intensity
of red to green fluorescence (here
shown as grades of gray) indicates
a high expression level of a specific
gene in the test sample
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tagging enzyme recognizes a specific site on
the linker sequences and cuts 9 nt downstream
into the tag sequence. The two resulting
populations of blunt ended linker-tag se-
quences are ligated to produce ditags that are
subsequently PCR amplified with primers
specific for the linker sequences situated in
each end. Following amplification the ditags
are cleaved from the linker sequences with the
anchoring enzyme and concatenated by liga-
tion to form a continuous sequence of sequence
tags. Sequencing of the concatenated sequence
tags will reveal the identity and the relative
frequency of the mRNA transcripts in the
original sample. SAGE is a fast method for
quantitatively analyzing mRNA expression
patterns. The experiments can in principle be
performed during a single day and do not re-
quire any out-of-the-ordinary laboratory
equipment.
In order to characterize new potential
markers evolving from gene expression screen-
ing experiments on a large number of samples,
a technique of generating tissue microarrays
on microscopic slides has been developed
[Kononen, 1998]. (fig. 5) In this technique
up to 1000 cylinders of 0.6 mm diameter are
punched from individual “donor” paraffin-
embedded tumor blocks and arrayed into a
new 45 x 20 mm paraffin block. The height
of the cylinders are approximately 3–4 mm
allowing up to two hundred consecutive sec-
tions to be cut from the block. Classical im-
munohistochemistry [Bubendorf, 1999] and
fluorescent in situ hybridization (FISH)
[Schraml, 1999; Richter, 2000] have been
successfully used to evaluate the clinical ap-
plicability of new candidate marker molecules,
whereas mRNA in situ hybridization requir-
ing conservation of intact mRNA in the ar-
rayed sections has been less well documented.
A modification of the original protocol for
generation of tissue microarrays [Fejzo, 2001]
enables generation of arrays from frozen tis-
sue in order to enhance qualitative and quan-
titative properties of problematic immuno-
histochemistry applications and especially
mRNA ISH assays.
Figure 5. A small region of a tissue microarray (96 spots). Each tissue spot has a diameter of 0.6 mm. Bottom:
Higher magnification images of three HE-stained specimens. (Adapted from Kallioniemi O-P. Biochip tech-
nologies in cancer research. Ann Med 2001; 33: 142–7.)
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5.2.2 Homogeneous hybridization assays
Detection of single nucleotide differences with
allele-specific oligonucleotide probes (ASO
probes) was described in 1979 [Wallace,
1979] and used to detect a mutation in the
beta-globin gene causing sickle-cell anemia
in 1983 [Conner, 1983]. Hybridization of
target specific oligonucleotides have been used
in a vast number of nucleic acid detection sys-
tems but are inheritedly restricted by a cer-
tain degree of cross-reaction when used for
quantitative detection of single nucleotide
differences.
Molecular beacon technology [Tyagi, 1996]
combines the simplicity of direct hybridiza-
tion with an enhanced capacity for discrimi-
nation between single nucleotide differences.
Molecular beacons are oligonucleotide probes
with a stem-and-loop structure consisting of
a central target-complementary region that
is flanked by two 5–7 nt arm sequences which
are unrelated to the target sequence but
complementary to each other (fig. 6). The
stem is formed by annealing of the two arm
sequences. A fluorescent moiety is coupled to
one of the arms of the probe and a non-fluo-
rescent quenching moiety to the other. When
the probe is in the closed state, the the
fluorophore and the quencher are in close ap-
position rendering the fluorophore unable to
fluoresce. When the probe encounters a tar-
get nucleic acid, the stem opens due to the
greater binding energy of the target comple-
mentary central loop sequence to the target,
as compared to the binding energy of the self-
annealing arm sequences. This forces the
fluorophore and the quencher apart from each
other and allows the probe to fluoresce upon
illumination. Due to the conformation con-
straint of the molecular beacon probes, a
greater specificity can be achieved than with
conventional ASO probes [Bonnet, 1999].
Molecular beacons have been successfully used
in real-time PCR applications for detection
of single nucleotide substitutions causing
drug resistance [Piatek, 1998] and multiplex
detection of pathogenic retroviruses [Vet,
1999]. Molecular beacons have also been used
to detect specific mRNAs in living cells with-
out prior amplification [Sokol, 1998]. Fluo-
rescent resonance energy transfer has been
utilized to create molecular beacons that are
brighter and simplify multiplexing as differ-
ent beacons can be excited with a common
monochromatic light source [Tyagi, 2000].
5.2.3 Enzyme dependent detection assays
Allele-specific ligation [Landegren, 1988]
utilizes the enzyme specificity of DNA ligase
Figure 6. The principle of operation (A) and struc-
ture (B) of molecular beacons. The self-complemen-
tary hairpin stem of the molecular beacon keeps the
fluorophore (EDANS) and the quencher (DABCYL)
in close apposition in the absence of target template.
When the molecular beacon hybridizes to a specific
target the hairpin structure is forced to open up, caus-
ing the probe to fluoresce as the fluorophore is re-
leased from the quencher. (Adapted  from Tyagi, S
and Kramer FR. Molecular Beacons: Probes that fluo-
resce upon hybridization. Nature Biotechnology
1996; 14: 303–8.)
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to covalently join two sequence-specific oli-
gonucleotide probes adjacently annealed on a
target DNA sequence. This technique was the
first model for utilizing enzyme-specificity to
detect single nucleotide substitutions. This
technology has led to the development of pad-
lock probes [Nilsson, 1994; Nilsson, 1997].
Padlock probes are linear oligonucleotides of
approximately 90 nt (80–200) length with a
target specific sequence of approximately 20
nt in each end. The padlock probes are circu-
larized by annealing the template specific 3’-
and 5’-regions adjacently on a target template
and ligating their outer ends. Since DNA and
RNA are helical molecules, the formed du-
plex is coiled at the annealing site one com-
plete turn per 10 base pairs. Circularization
of the padlock probe prevents unwinding of
the helical structure, and the probe will thus
be catenated to the target DNA despite de-
naturation of the specific part of the probe
from the target sequence.
Minisequencing (single nucleotide
primer extension) has become the most
widely used technique for single nucleotide
detection (fig. 7). This technique utilizes the
specificity of a DNA polymerase (or alter-
natively a reverse transcriptase) to incorpo-
rate a single nucleotide at the 3’-end of a
sequence-specific primer [Syvanen, 1990].
Minisequencing is typically performed in
solid phase assays to detect point mutations
in amplified PCR products [Syvanen, 1992;
Syvanen, 1992; Singer-Sam, 1992]. In such
applications, the PCR amplicons are labelled
using a biotinylated primer in the amplifi-
cation reaction. Following amplification, the
PCR product is captured on a streptavidin
coated solid phase and quantitatively de-
tected by incorporating labelled nucleotides
to a target specific primer annealed imme-
diately adjacently to the polymorphic site.
Tritium has been commonly used as a de-
tection label in combination with scintil-
Figure 7. The minisequencing principle. 1. Biotinylation during amplification using a labeled primer. 2.
Affinity-capture. 3. Washing and denaturation of the double-stranded PCR amplicons. 4. Annealing of the
minisequencing primer. 5a and 5b separate detection of PCR products by minisequencing primer extension
with single labeled nucleotides. (Adapted from Syvanen A-C et al. A primer-guided nucleotide incorpora-
tion assay in the genotyping of apolipoprotein E. Genomics 1990; 8: 684–92.)
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lating microtiter plates [Ihalainen, 1994].
Multiplexing of minisequencing reactions
has been achieved using fluorescent labels
[Pastinen, 1996; Pastinen, 1997] and a ho-
mogenous assay format has been described
utilizing fluorescent resonance energy trans-
fer (FRET) between a donor fluorophore at
the 5’-end of the primer and and acceptor
fluorophores coupled to dideoxy termina-
tor nucleotides [Chen, 1997; Chen, 1997].
Minisequencing has been used for quantifi-
cation of rare mRNA transcripts [Ikonen,
1992; Singer-Sam, 1992] and as a detection
method on microarrays [Pastinen, 1998;
Pastinen, 2000]. A number of commercial
products have been developed based on the
minisequencing technology, the most com-
mon application being SNP detection.
5.3 Amplification techniques
5.3.1 Competitive RT-PCR
Reverse transcriptase polymerase chain reac-
tion (RT-PCR) has been the mainstream
method of mRNA amplification since the
advent of PCR in 1986 [Mullis, 1986; Mullis,
1987; Saiki, 1986]. The first quantitative RT-
PCR protocols relied on coamplification of an
internal standard consisting of in vitro-gen-
erated DNA or RNA with the wild type tem-
plates [Wang, 1989; Becker-Andre, 1989;
Gilliland, 1990]. In this type of assay the ini-
tial copynumber of the wild type template is
estimated from the ratio of endpoint wild type
to internal standard PCR product following
amplification. Several different methods of
end-point detection of PCR products have
been described [Ikonen, 1992; Pannetier,
1993; Alard, 1993]. In an early application
of this technique Piatak and colleagues quan-
titatively determined the viral load of HIV-
infected patients [Piatak, 1993]. When care-
fully optimized to minimize differences in
reaction kinetics between the competing tem-
plates in the reaction and excluding any pos-
sible sources of nonspecific amplification, ac-
curate quantitation over a dynamic range of
6 orders of magnitude can be achieved with
this type of technique [Jalava, 1993].
Figure 8. Ratio of fluorescein to rhodamine fluorescence of a dual-labelled hydrolysis probe, monitored at
each cycle during a kinetic PCR amplification of 10-fold dilutions of the target template. Threshold cycle
values are typically calculated by determining the point at which the fluorescence exceeds ten times the
standard deviation of the baseline. (Adapted from Wittwer CT et al. Continuous fluorescence monitoring of
rapid cycle DNA amplification. Biotechniques 1997; 22: 130–8.)
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5.3.2 Kinetic RT-PCR
Kinetic or real PCR technology enables fluo-
rometric monitoring of the accumulating
PCR products during cycling. (fig. 8) In its
simplest form accumulating fluorescence
from an intercalating dye is measured
[Higuchi, 1992]. Discrimination between
coamplified products can be achieved by
melting curve analysis provided that the
amplified products differ in length. Draw-
backs of this technique is that any nonspe-
cific amplification will contribute to the ac-
cumulation of fluorescence and thus decrease
sensitivity and undermine the quantitative
accuracy. Detection technologies based on
product identification by hybridization en-
able increased quantitative accuracy and also
allows the use of internal standards in a com-
petitive fashion. In the commercially avail-
able TaqMan assay® (PE Biosystems) quan-
tification is obtained by monitoring decrease
in fluorescein quenching by rhodamine fol-
lowing exonuclease cleavage of dual-labelled
probes that have hybridized to the accumu-
lating PCR amplicons [Holland, 1991;
Livak, 1995; Gibson, 1996]. A commonly
used commercial assay for Lightcycler® in-
strument (Roche) is based on fluorescent en-
ergy transfer (FRET) of CY5 to fluorescein
between probes that anneal adjacently on the
accumulating PCR products [Wittwer,
1997]. Alternative detection principles based
on FRET include molecular beacons [Tyagi,
1996], energy transfer primers [Nazarenko,
1997] and dye-labeled oligonucleotide liga-
tion [Chen, 1998]. Quantitation in real time
assay systems is done from data points gath-
ered during the exponential phase of ampli-
fication. Several commercial systems use ex-
trapolation of a threshold cycle at which the
accumulating fluorescence from the PCR
product exceeds the baseline. The original
amount of template in the sample is math-
ematically derived from the threshold cycle.
The kinetic PCR systems offer the conve-
nience of quantitation during cycling which
simplifies assay procedures and minimizes
the risk of sample contamination. They do
not however eliminate the need of an appro-
priate internal standard if accurate quantita-
tion is to be achieved.
5.3.3 In situ PCR
In situ PCR of DNA targets was first de-
scribed in 1990 [Haase, 1990]. In situ RT-
PCR [Nuovo, 1992] enables sensitive detec-
tion of rare mRNA transcripts within cells
and tissues as well as co-localization of
mRNA transcripts and proteins when com-
bined with immunohistochemistry [Matsu-
ki, 1992; Gosztonyi, 1994]. Technical prob-
lems specific for in situ PCR include loss of
localization due to diffusion of amplification
products as well as primer oligomerization
and incorporation of labeled nucleotides into
background DNA [Nuovo, 2001]. Several
detection methods such as exonuclease cleav-
age of dual-labeled probes [Holland, 1991],
molecular beacons [Tyagi, 1996] and energy
transfer primers [Nazarenko, 1997] that al-
low monitoring of the accumulating PCR
amplicons during cycling, are directly ap-
plicable to In situ RT-PCR. A technique
based on universal energy-transfer labelled
primers has been described [Nuovo, 1999]
significantly simplifying the experimental
procedures of In situ PCR.
5.3.4 Isothermal RNA amplification
Isothermal RNA amplification (Self-Sus-
tained Sequence Replication, 3SR, Tran-
scription-based Amplification System, TAS
or Nucleic Acid Sequence-Based Amplifi-
cation, NASBA) involves a combination of
three enzymes to generate a logarithmic am-
plification of an RNA template without
temperature cycling. (fig. 9) In the initial
report [Kwoh, 1989], the original RNA
template is reverse transcribed using AMV
reverse transcriptase and a primer with a
T7 RNA polymerase promoter sequence at
the 5’-end to generate a (–) cDNA strand.
The RNA-DNA hybrid is heat-denaturated
and a second primer complementary to a
region at the 3’-end of the cDNA initiates
Jakob Stenman
26
reverse transcription of a second DNA
strand, thus producing a double stranded
DNA template with a T7-polymerase pro-
moter region. Subsequently the T7 RNA
polymerase replicates a large number of
RNA transcripts from the double stranded
DNA template, resulting in a 2–5 x 106-
fold increase in the copy number of the
original target sequence after 4 cycles. In a
modification of this technique RNase H was
added to the reaction resulting in degrada-
tion of the RNA in the RNA-DNA hybrids
as the first reverse transcription reaction
Figure 9. The principle of isothermal RNA amplification (Self Sustained Sequence Replication 3SR, Nucleic
Acid Sequence-Based Amplification, NASBA). Amplification proceeds through a continuous cycle of re-
verse transcription and transcription reactions to replicate an RNA target by means of cDNA intermediates.
The generation of double stranded DNA targets for the T7 RNA polymerase (5) is dependent on RNase
digestion of the RNA in the intermediate RNA-DNA hybrids. (Adapted from Guatelli, JC et al. Isothermal,
in vitro amplification of nucleic acids by a multi-enzyme reaction modeled after retroviral replication. Proc
Nat Acad Sci USA 1990; 87: 1874–8.)
progresses [Guatelli, 1990; Compton,
1991]. This improved procedure enabled
isothermal amplification at 41° C for ap-
proximately 90 minutes. Molecular beacons
[Tyagi, 1996] have been used to enable real-
time detection during isothermal RNA
amplification [Leone, 1998].
5.3.5 Probe amplification techniques
Ligase chain reaction (LCR) [Wu, 1989;
Barany, 1991] utilizes two probe pairs analo-
gous the sequence of the two respective strands
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of the target nucleic acid. The reaction pro-
ceeds exponentially as adjacently annealed
probes are enzymatically ligated and form a
template for a pair of complementary probes.
The method possesses the enzyme specificity
of allele-specific ligation. This relatively
simple amplification technique has been used
for DNA amplification in numerous genotyp-
ing and clinical applications. Rolling circle
amplification (RCA) is a probe amplification
technique in which a circular DNA 34 nt or
longer acts as template for amplification [Fire,
1995; Lizardi, 1998]. (fig. 10) When a DNA
polymerase with strand displacement capac-
ity is utilized, the reaction proceeds isother-
mally creating a single linear complementary
DNA strand consisting of multiple tandem
repeats of the of the template sequence. Nu-
merous modifications to the RCA protocol
have been published. Perhaps the most poten-
tial properties of this amplification technique
is the possibility to generate localized ampli-
fication products for in situ detection of DNA
[Zhong, 2001] and mRNA [Zhou, 2001].
Figure 10. Schematic for detecting small target sequences (A) or point mutations (B) using rolling circle
amplification. (Adapted from Zhong, XB et al. Visualization of oligonucleotide probes and point mutations
in interphase nuclei and DNA fibers using rolling circle DNA amplification. Proc Nat Acad Sci USA 2001;
98: 3940–5.)
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Aims of the present study
The aim of this study was to utilize molecu-
lar biology techniques to develop novel prog-
nostic methods for the management of solid
tumors. Squamous cell carcinomas of the head
and neck region and the uterine cervix have
served as model diseases for this purpose. The
specific aims of this study were:
1) To develop a method for detecting occult
malignant cells in the circulation of pa-
tients with cancer of the uterine cervix,
based on detection of squamous cell car-
cinoma antigen mRNA in peripheral
blood.
2) To develop a method to enable accurate
quantification of the relative levels of two
highly homologous mRNAs occurring in
a clinical sample.
3) To determine the prognostic value of ac-
curately measuring the ratio of SCCA2
to SCCA1 mRNA in tumor tissue of pri-
mary squamous cell carcinomas of the
head and neck.
4) To mathematically estimate the degree of
variation caused by stochastic factors in
techniques striving to quantify the abso-
lute and relative levels of molecules in
highly diluted solutions.
5) To empirically test the accuracy of a
highly optimized competitive RT-PCR
based assay to quantify relative levels of
highly homologous mRNAs, in relation
to the mathematically estimated optimal
accuracy at low levels of target template
molecules.
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1.1 Blood samples
Single 3 ml blood samples were drawn from
patients under follow up for squamous cell
carcinoma of the uterine cervix and from con-
trol subjects (I) Two to five 10 ml blood
samples were drawn from cervical cancer pa-
tients, head and neck cancer patients as well
as from corresponding control subject under-
going invasive therapy, before during and af-
ter treatment (V). All blood samples were
drawn in Vacutainer EDTA tubes (Becton
Dickinson, Rutherford, NJ). In order to avoid
contamination from epithelial cells from the
skin, at least one tube was drawn for other
purposes before collection of the sample ana-
lyzed in RT-PCR.
1.2 Tissue samples
Grossly prepared tissue samples from three
patients treated for squamous cell carcinoma
of the uterine cervix was used as positive con-
trols for detection of SCCA mRNA in pe-
ripheral blood (I). In order to study the rela-
tive mRNA expression of the SCCA1 and
SCCA2 genes in malignant and normal tis-
sue we analyzed banked tumor tissue speci-
mens from 30 patients with primary and 11
patients with recurrent squamous cell head
and neck tumors and 19 normal mucosal epi-
thelium specimens from the head and neck
region of 16 patients surgically treated for
various conditions. The condition of the
sample and the proportions of different cell
types present were determined from a tolui-
dine-blue stained microscopic frozen section
and five adjacently located 10 µm sections
were transferred to a reaction tube for extrac-
Materials and Methods
tion of total RNA (II, III). Tissue samples
had been stored at –80°C (I) and at –40°C
(II,III) until analysis. The total amount of
tumor tissue samples was limited by the avail-
ability of banked specimens from different
patients (II, III).
1.3 Cultured cells
Epidermoid carcinoma cell line A431 (ATCC,
Rockville, MD) were cultured and used for
cell spiking experiments in order to determine
the detection limit of the RT-PCR assay (I)
and to evaluate the quantitative accuracy of
the RT-PCR assay at low template concentra-
tions (V).
1.4 Patients and follow-up
characteristics
In order to study the presence of occult epi-
thelial cells in the circulation of cervical can-
cer patients we studied samples from 15 pa-
tients under follow up after treatment for can-
cer of the uterine cervix and 24 controls (I).
To determine the prognostic value of measur-
ing the mRNA ratio of SCCA1 and SCCA2
in head and neck cancer we studied tumor
tissue specimens from 30 patients with pri-
mary squamous cell tumors and 11 patients
with recurrent tumors (II, III). In study V the
original aim was to study the possible release
of tumor cells into circulation during various
forms of invasive treatment. 385 blood
samples were obtained from cervical cancer
patients undergoing intracavitary radiation
therapy, from head and neck cancer patients
undergoing radical surgery and from corre-
sponding control subject undergoing surgery
1. Patients and samples
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to the head and neck region for other causes.
All of the patients included in the studies had
been treated with curative intent and in-
formed consent was obtained from all patients
and controls. The studies have been approved
by the ethical committees of the Dept. of
Gynecology and Obstetrics (I, V) and the
Dept. of Otorhinolaryngology at the Helsinki
University Central Hospital (V) and the Joint
Ethical Committee of the Turku University
and the Turku University Central Hospital
(II, III).
2. Detection and quantification of SCCA mRNA transcripts
2.1 RNA extraction procedures
Total RNA was extracted from microscopic
tissue sections by transferring five adjacent
10 µm frozen sections from each sample di-
rectly into a chaotropic Lysis buffer (Qiagen,
Hilden, Germany) and centrifuged through
Qiashredder spin columns (Qiagen) to shear
high molecular weight DNA. Total RNA was
extracted from the lysates by centrifugation
through RNeasy spin columns (Qiagen) where
RNA adsorbs to a silica membrane under
chaotropic conditions. Prior to elution in
diethylpyrocarbonate (DEPC) treated water
the RNA extracts were DNA digested in the
column membranes according to the manu-
facturers instructions (II, III).
mRNA was extracted from peripheral
blood samples according to two different pro-
tocols. In the early stages of the study (I) blood
samples were hemolyzed in a hypotonic solu-
tion consisting of 1.5 volumes of DEPC-
treated water for 5 min. Leukocytes were
pelleted and transferred to a 4.0 M guanidium
thiocyanate based chaotropic buffer [Chomc-
zynski, 1987] and lysed by vortexing. mRNA
was directly captured from the 2:1 diluted
lysate using biotinylated oligo-dT probes and
captured on streptavidin coated paramagnetic
particles (Promega, Madison, WI). At a later
stage (V) hemolysis was done by hypotonic
shock by 10:1 dilution of blood samples in
cold DEPC-treated water and neutralization
after 30 sec with 0.1 vol of 10 x PBS. The
pelleted leukocytes were lysed in 5.0 M
guanidium thiocyanate based buffer, centri-
fuged through Qiashredder spin columns
(Qiagen) and total RNA was extracted using
RNeasy spin columns (Qiagen). mRNA was
subsequently oligo-dT captured from the to-
tal RNA eluate on the wall of 0.2 ml strept-
avidin coated PCR tubes (Roche diagnostics,
Basel, Switzerland).
2.2 Primer design, verification of PCR
products and end-point-detection
To optimize stringency of the PCR (II, III,
V), all primers were designed to have a 5’ or
central domain binding to the template stron-
ger than the 3’ pentamer. (fig. 11) This was
done to ensure that elongation would pursue
only after annealing of the entire length of
the primer [Rychlik, 1995]. The formation
of primer dimers was eliminated by design-
ing all of the PCR primers so that any pos-
sible primer-primer duplexes with protrud-
ing 5’ end enabling formation of amplified
dimers possessed considerably weaker bind-
ing energies than the 3’-pentamers of the
primer to template duplexes. Oligo 5.0 primer
analysis software (National Biosciences, Ply-
mouth, MN) was used as an aid in designing
and analyzing PCR primers. In order to gain
enough freedom to design primers conferring
to the above criteria, we did not in any way
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restrict the formation of primer-primer du-
plexes with protruding 3’ overhangs that are
unable to amplify.The PCR amplicon spans
the exon 2-3 junction of the SCCA1 and
SCCA2 genes. The minisequencing primers
both bind symmetrically on the exon 2-3
junction. The competitive effect imposed by
coamplification of genomic DNA was mini-
mized by DNase digestion of the total RNA
extracted from the samples (II, III, V) and by
further capturing of mRNA from total RNA
extracts (V). PCR products were verified by
cycle sequencing on an ABI PRISM 310 ge-
netic analyzer (Applied Biosystems, Foster
City, CA) (I, II) and Southern blot analysis
using a 32P-labelled 21-mer oligonucleotide
probe (I). A nested PCR protocol was used
for all applications. PCR products were end-
point-detected by agarose gel electrophoresis
and ethidium bromide staining (I) and quan-
tified in a beta counter by solid phase minise-
quencing using 3H-labelled nucleotides and
96-well scintillating microtiter plates [Iha-
lainen, 1994] (II, III, V).
2.3 Internal standard construction
The SCCA1 and SCCA2 templates differ
within the PCR amplicon at positions 206,
211 and 212 of the SCCA2 cDNA sequence
(Genebank, accession number: U19557). An
internal standard was constructed by generat-
ing an additional A to T mismatch at posi-
tion 206 of the SCCA2 cDNA using modi-
Figure 11. Sequences and internal stability of the PCR primers used for co-amplification of the SCCA1,
SCCA2 and internal standard templates. Binding energy was calculated by the nearest neighbor method
using Oligo 5.0 software. ∆G = ∆H - T∆S. ∆H = change in enthalpy, T = temperature (25° C), ∆S = change
in entropy.
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Methods
3.1 Evaluation of the SCCA mRNA ratio
assay
The Mann-Whitney U-test was used to ana-
lyze the statistical significance of the differ-
ences between tumor groups and normal epi-
thelium (III). Survival curves were plotted
according to the Kaplan-Meier method. The
logrank test was used to calculate the statis-
tical significance of the difference in recur-
rence-free survival between groups and to
evaluate the possible confounding effect of
commonly used prognostic factors and differ-
ent cell types present in the samples. The rela-
tive risk of recurrence was calculated and the
confidence interval for the relative risk was
calculated according to a method developed
for clinical trials [Simon, 1986] (III).
3.2 Estimates on sampling variation at
low template concentrations
For statistical estimation of the absolute
amounts of template molecules present in
3. Statistical analyses
an aliquot pipetted from a sample of a
known concentration (IV, V), a normal dis-
tribution was assumed for templates present
at a level of 40 copies or more whereas the
Poisson distribution was applied for calcu-
lations concerning less than 40 template
copies. The probability of a certain ratio of
wild type to reference templates to be
present in an aliquot containing a known
ratio of templates was calculated by multi-
plying the distribution-based estimated
probabilities for each possible absolute
amount of wild type and reference templates
present in the sampled aliquots. As the same
ratio can arise from different combinations
of absolute copynumbers of the respective
templates, the probability of a certain ratio
was estimated by summing the probabili-
ties of the different copynumber combina-
tions resulting in the same ratios. The prob-
ability distributions and confidence inter-
vals of a ratio of two templates in an aliquot
was estimated from the cumulative prob-
abilities of the most frequent ratios.
fied primers and PCR (II). The generated se-
quence was amplified with the outer PCR
primers, cloned into the pCR® II vector
(Invitrogen, Carlsbad, CA) and sequenced
from both ends on an ABI 310 genetic ana-
lyzer (Applied Biosystems) using the ABI
Prism dRhodamine terminator cycle sequenc-
ing kit. One thousand (II, III) or twenty (V)
copies of the non-linearized vector containing
the modified SCCA2 sequence was included
in the PCR reactions as an internal standard.
2.4 Measurement of SCCA protein
SCCA protein was measured by immunoas-
say on an IMx analyzer (Abbott, Abbott Park,
IL) using the IMx SCC kit from the manufac-
turer (I).
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Results and Discussion
1.1 Principles for detection and quanti-
fication of SCCA mRNA levels
We have utilized the tissue-specific expres-
sion of the SCCA1 and SCCA2 genes to de-
tect epithelial cells in blood and to measure
the expression levels of the two genes in tis-
sue samples containing a mixture of cell types.
Non-quantitative RT-PCR amplification was
used to detect occult epithelial cells in the
circulation of patients with cervical cancer (I)
according to the principle described by Smith
and colleagues [Smith, 1991], and a quanti-
tative RT-PCR was developed in order to
study the relative expression levels of the
SCCA genes in tumor specimens of head and
neck cancer patients (II, III). The latter
method has been used with slight modifica-
tions to study factors affecting the quantita-
tive accuracy of sensitive amplification assays
at different levels of input template (IV, V).
The principle of quantifying the expression
levels of highly homologous transcripts in
relation to each other was originally described
for fibrillin alleles in patients with Marfan’s
syndrome [Karttunen, 1996]. As highly ho-
mologous mRNA transcripts are likely to be
similarly affected by nonspecific factors in-
volved in mRNA degradation, the relative
level of the transcripts is expected to remain
fairly constant despite sample to sample varia-
tions in RNA degradation during handling
and storage. In addition the two transcripts
are likely to be subjected to similar variations
in efficacy of RNA extraction procedures and
during reverse transcription. The 98% ho-
mologous [Schneider, 1995] and tissue spe-
cifically expressed [Cataltepe, 2000] SCCA
genes have provided suitable targets for such
a quantitative setup.
The equivalence of replication efficiencies
has been shown by mathematical modeling
to be the key feature for achieving optimal
quantitative precision in co-amplification
based PCR systems [Nedelman, 1992]. In
accordance with this, amplification of inter-
nal standards and wild type templates with
common primers has been unequivocally
shown to yield superior quantification accu-
racy than amplification of standards and wild
type templates with separate primers [Raey-
maekers, 2000]. We have striven to take the
concept of equivalence of replication efficien-
cies further yet by designing PCR primers
common for SCCA1, SCCA2 and the inter-
nal standards that produce amplicons of equal
length and close to identical base pair com-
position. This way secondary structures caused
by folding of the single stranded PCR
amplicons after denaturation are unified, and
subsequently the differences in annealing and
elongation efficiencies of the primers to the
different target templates are minimized. To
optimize PCR primer hybridization features
and PCR product nucleotide composition and
length, 22 primers equally specific to SCCA1
and SCCA2 were designed, synthesized and
tested under different cycling conditions.
With the primers chosen for the final assay
for SCCA mRNA (II, III, V) the amplicons of
SCCA1, SCCA2 and an internal standard were
coamplified, producing a single 108 bp
1. Design of the RT-PCR assay for accurate quantification of
relative transcript levels
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amplicon. These primers amplified the tar-
get templates over a ±5 °C range of anneal-
ing temperatures. With the final reaction con-
ditions no primer dimers or other non-spe-
cific amplification could be visualized by
ethidium bromide staining (fig. 12).
Figure 12. Coamplification of SCCA1, SCCA2 and internal standard templates. Ethidium bromide stained
agarose gel displaying the single 108 bp band including all three amplicons. All nested PCR reactions were
amplified to the plateau. In this way the absolute amount of PCR product in the reactions originally contain-
ing various amounts of target template, was unified to fit into the dynamic range of the minisequencing
detection assay. The close-to-identical reaction kinetics of the three templates enabled accurate quantifica-
tion of their relative levels in the endpoint PCR products. Lanes 1–6: patient tissue samples consisting of five
10 µm microscopic frozen sections. Lane 7: phiX-DNA marker.
Figure 13. Capacity of the minise-
quencing assay to discriminate be-
tween templates differing at single
nucleotide position. The PCR
products derived from the SCCA1,
SCCA2  and two internal standards
(StandC206 and StandT206) dif-
fering at position 206 of the
SCCA2 cDNA sequence were
mixed and minisequenced with
with four different 3H-labelled
nucleotides (dGTP, dATP, dTTP
and dCTP).
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1.2 Measuring range
In order to determine the measuring range of
assay, we amplified dilutions of SCCA1 and
SCCA2 cDNA in a 1:1 ratio over a concen-
tration range of 102 to 109 copies together
with different amounts of internal standard
(publication II, fig. 1). The ratio of SCCA1
and SCCA2 PCR products remained constant
when the amount of wild type templates ex-
ceeded that of the internal standard. This re-
sulted in a dynamic range of six orders of
magnitude when using more than 1000 mol-
ecules of internal standard in the reactions (fig.
13). When the assay was optimized for ex-
treme sensitivity, using 20 molecules of in-
ternal standard and in vitro transcribed cRNA
templates, the measuring range was limited
to 4 orders of magnitude (publication V, fig
I). We strived to gain a wide measuring range
by systematically amplifying all nested PCR
reactions to the plateau phase. By doing this,
the endpoint PCR product is brought into
the dynamic range of the minisequencing
endpoint detection assay, irrespectively of the
absolute amount of input wild type templates.
Quantitative detection on the or plateau phase
of amplification is possible in coamplification
systems provided that the amplification effi-
ciencies of the coamplified templates are equal
[Raeymaekers, 2000]. In such a setting the
amplification efficiencies of the different tem-
plates will be equally affected by factors lim-
iting exponential amplification and the ratio
of the templates will remain unchanged de-
spite saturation of the reaction. The minise-
quencing assay provided accurate discrimina-
tion of single nucleotide sequence differences
in the coamplified SCCA1, SCCA2 and in-
ternal standard PCR products (fig. 14). In
addition, the assay has an exceptional signal
to noise ratio which is explained by the great
difference in binding affinity between labeled
nucleotides enzymatically incorporated to an
oligonucleotide primer and non-specific ad-
sorption of nucleotides to any of the compo-
nents present on the solid phase.
1.3 Quantitative accuracy
The accuracy of the assay for measuring rela-
tive levels of SCCA1 and SCCA2 mRNA (II,
III) was determined from test samples of
pooled cDNA from six normal epithelium
Figure 14. Dynamic range of the RT-
PCR assay for quantifying the relative
levels of SCCA and internal standard.
When mixing 10 000 molecules of
the internal standard (Stand T) with
10-fold dilutions of the SCCA1 and
SCCA2 transcripts the dynamic range
was 6 orders of magnitude.SCCA1/SCCA2 molecules added
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samples and six squamous cell carcinoma tu-
mor samples from the head and neck region.
The test samples were included in ten indi-
vidual sample series and analysed in separate
experiments as single samples. The 99% con-
fidence intervals of the means were 0.23 to
0.27 (mean=0.25) and 0.37 to 0.41 (mean
0.39) for the normal epithelium and squamous
cell carcinoma tumor test samples, respectively
(publication II, fig. 2). The inter-assay coeffi-
cient of variation (CV) was 9% for the nor-
mal, and 5% for the tumor test samples. 1000
copies of a non-linearized plasmid containing
the internal standard sequence was included
with the wild type SCCA 1 and SCCA2 tem-
plates in the amplification reactions resulting
in co-amplification of the three templates. The
main function of the internal standard was to
ensure that sufficient amounts of the wild type
templates were present to yield an accurate
ratio of the two wild type templates (II, III,
V). The internal standard also served as a qual-
ity control, as a decrease in amplification of
the standard not accompanied by an increase
in amplification of the wild type templates
would indicate the presence of inhibition or
nonspecific competition in the PCR reactions.
When optimizing the assay for extreme sensi-
tivity (V) we observed that the degree of cross-
contamination of negative samples was effi-
ciently avoided when as little as 20 molecules
of internal standard was used (V). This could
indicate that amplification from contaminat-
ing DNA or RNA often is derived from single
or minimal amounts of template molecules
that can be competitively suppressed by even
as little as 40 single stranded copies of an in-
ternal standard.
The concept of using a highly homologous
reference template enables highly accurate and
reproducible quantification over a wide range
of input template concentrations. This tech-
nique is not restricted to the endpoint detec-
tion by minisequencing, but can be used in
any quantitative system capable of distin-
guishing highly homologous PCR products.
Kinetic or real-time PCR technology has be-
come the mainstream methodology for quan-
titative applications mainly due to simplified
assay procedures and diminished risk of cross-
contamination of samples. Combining a de-
tection technology capable of distinguishing
single nucleotide differences such as molecu-
lar beacons [Tyagi, 1996] to kinetic PCR,
NASBA or other alternative kinetic amplifi-
cation techniques would produce a versatile
technology for accurate quantification of rare
mRNA transcripts. Thus the benefits of com-
petitive and kinetic amplification approaches
could be combined.
1.4 Stochastic considerations
When optimizing the RT-PCR assay for
maximal sensitivity (V) we noted that the
variation in quantitative accuracy increased
dramatically when less than 1000 copies of
target template molecules were present. This
phenomenon has earlier been termed the
Monte Carlo effect [Karrer, 1995]. The ob-
served variation was however much greater
than suggested by estimations based on nor-
mal and Poisson distributions that have been
used in limited dilution assays [Sykes, 1992].
In order to evaluate to what degree the ob-
served variation depended on methodologi-
cal inaccuracy and to what degree it could be
attributed to stochastic sampling variation,
we developed an algorithm for calculating the
stochastic variation of the resulting ratio of
two templates when sampling from a solu-
tion containing the two templates at a known
ratio (IV). This algorithm, taking in account
the multiplicative effect imposed by the varia-
tion in the absolute numbers of both wild
type and reference template copies, predicted
close to 10-fold differences when aiming at
sampling an aliquot containing 8 copies of
each of the templates. This variation decreases
rapidly when the amount of templates in-
creases, being largely negligible at levels
above 1000 molecules per reaction (fig. 15,
publication III: fig. 1 and table 1). In order
to compare the statistically estimated sam-
pling variation with the empirically observed
variation, we co-amplified a 5-fold dilution
series of mRNA from SCCA-producing A431
cells corresponding to approximately 8–1000
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2.1. Detection of SCCA mRNA in
peripheral blood
Circulating epithelial cells were detected in
six of 15 cervical cancer patients under fol-
low-up using a non-quantitative RT-PCR for
SCCA (I). Of the patients testing positive, five
had a diagnosis of epidermoid carcinoma and
one had an adenomatous carcinoma (publica-
tion I, table 1). Four patients experienced re-
current disease during a 24-month follow up
period and three of these had tested positive
in the RT-PCR for SCCA while still in remis-
sion. One of the patients did not, however,
test positive despite progressive disease at the
time of sampling. Interestingly, two of 24
control subjects tested positive, both being
pregnant women at term (publication I, table
2). This finding is possibly explained by re-
lease of squamous epithelial cells due to pro-
teolytic processes in the uterine cervix dur-
ing the last days of pregnancy. Due to the
small number of patients in this study, no
conclusions regarding the prognostic poten-
tial of this technique could be made. This
study however, clearly showed that the tis-
2. Clinical Observations
Figure 15. Variation imposed by
stochastic distribution of rare tem-
plate molecules. The 95% confi-
dence intervals of the sampling
variation is shown separately for
low concentrations of single tem-
plates and for the ratio of a target
and reference template.
SCCA mRNA transcripts, with 20 mol-
ecules of a double stranded DNA internal
standard. This experiment was repeated 12
times and the 95% confidence intervals were
calculated for each sensitivity level and com-
pared with the corresponding confidence
intervals of the statistically predicted sam-
pling variation. We observed that stochastic
factors affecting sampling explain a major
part of the great variation observed when
quantifying relative levels of two rare tem-
plates (publication V: fig III).
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sue-specific expression of squamous cell car-
cinoma antigen can be used to detect occult
epithelial cells.
The sensitivity of the assay was determined
to be 10 cells among 106 leukocytes as de-
fined by cell spiking experiments with cul-
tured A431 epidermoid carcinoma cells. A
total of 4 PCR reactions were amplified from
each of the blood samples using a nested
primer protocol. The result was considered
positive if the correct PCR product was am-
plified in one or more of the PCR reactions.
The non-quantitative assay setup did not al-
low definitive exclusion of the possibility that
some positive signals would have been derived
from low-level background expression in leu-
kocytes. The minimal amount of specific tem-
plate present in the samples is reflected by
the fact that we were not able to amplify the
SCCA derived amplicon in more than two of
four reactions from any of the patient samples.
It is possible that shedding of malignant cells
in circulation is not a continuous phenom-
enon, but rather occurs at intervals. In addi-
tion the circulation time of cells of epithelial
origin before being trapped in the capillary
beds of the lung, liver or other peripheral sites
might be relatively short as the total blood
volume is circulated on an average once each
minute in a person at rest [Despopoulos,
1986].
The observation that cells were released
from the cervix during the last days of preg-
nancy prompted us to develop a competitive
RT-PCR for quantitative detection of mini-
mal levels of the SCCA1 and SCCA2 tran-
scripts in blood samples obtained in connec-
tion with invasive therapy of squamous cell
carcinomas (V). The original aim was to evalu-
ate the effect of invasive therapy on cell-shed-
ding into circulation. We chose to study head
and neck cancer patients undergoing radical
surgery and cervical cancer patients undergo-
ing intracavitary radiation therapy to the uter-
ine cervix. Especially the latter setting was
anticipated to bring about at least temporary
shedding of epithelial cells into circulation as
the intervention is relatively traumatic and
includes no restriction of the blood flow to or
from the cervical region. The technique al-
lowed reproducible detection of 40 copies of
SCCA cRNA template spiked in total RNA
from 1µg of total leukocyte RNA (publica-
tion V: figure 1). We did not however ob-
serve a rise in the level of SCCA mRNA fol-
lowing invasive treatment in any of the head
and neck or cervical cancer patient samples
(unpublished results).
The concept of detecting occult malignant
cells in peripheral blood by RT-PCR based
amplification of tissue-specific gene tran-
scripts was first described in 1991 [Smith,
1991]. During the passed decade a great num-
ber of techniques have been described using
tyrosinase [Smith, 1991], cytokeratins [Ko,
2000], PSA [Jaakkola, 1995; Henke, 1997],
PSM [Lintula, 1997] and many other genes
as targets for tissue specific RT-PCR amplifi-
cation. Early attempts were based on non-
quantitative techniques and highly variable
results were often referred to as illegitimate
expression by leukocytes and the existence of
expressed pseudogenes. Despite the expecta-
tions that real-time PCR technology would
solve these problems, as an increase in expres-
sion of the target gene could be quantitatively
distinguished from baseline expression, what-
ever the source, results are still quite modest.
To date, none of these techniques have reached
clinical practice. We conclude that the major
source of the variability observed with this
type of techniques are in fact due to the low
and variable amounts of occult malignant cells
present in the peripheral circulation at any
given time point.
2.2. Relative levels of SCCA2 and SCCA1
mRNA in head and neck tumor biopsies
Due to the low level of target template in the
blood samples we turned the focus to devel-
oping accurate techniques to quantify gene
expression in microscopic tissue sections. The
finding that the neutral and acidic isoforms
of SCCA in fact were products of two sepa-
rate genes, SCCA1 and SCCA2 [Schneider,
1995] spurred us to develop a method that
would enable accurate quantitation of the rela-
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tive expression levels of these two highly ho-
mologous genes. This led to the development
of an RT-PCR based technique that enabled
accurate quantification of the relative levels
of SCCA1 and SCCA2 mRNAs occurring in
biopsy specimens of tumor tissue and normal
epithelium. The measuring range of the as-
say (II, III) was 103–109 copies of input wild
type cDNA template (publication II: figure
1). In our material of 117 samples from mi-
croscopic frozen sections of normal epithelium
and tumor specimen 16 samples were ex-
cluded, as the observed SCCA2/SCCA1 ratio
was derived from less than one thousand cop-
ies of cDNA template. All observed CPM sig-
nals for SCCA1 and SCCA2 in the accepted
samples exceeded three times the baseline
determined from their respective negative
controls.
We applied this method to study a mate-
rial of banked tumor tissue specimens includ-
ing 30 primary head and neck tumors and 11
recurrent tumors from patients of which fol-
low up data was available from clinical records
(publication III: tables 1 and 2). We observed
that the relative levels of SCCA2 to SCCA1
mRNA was higher in all tumor groups than
in normal epithelial samples. In addition the
relative levels of SCCA2 to SCCA1 mRNA
was significantly higher in recurrent tumors
as well as in primary tumors that had eventu-
ally recurred in course of time, than in pri-
mary tumors of patients not experiencing a
recurrence (publication III: fig. 1). Statistical
analysis of recurrence free survival revealed a
relative risk of 7.2 (CI 1.2-13.3) of develop-
ing recurrent disease in patients with a pri-
mary tumor expressing mRNA of SCCA2 at
a high level in relation to SCCA1 (publica-
tion III: fig. 2). When analyzing other com-
monly used prognostic indicators in head and
neck cancer, the presence of metastases in re-
gional lymph nodes was in addition to a high
SCCA2 to SCCA1 mRNA ratio in the pri-
mary tumor, the only independent predictor
of disease recurrence in our material. There
was however no correlation between an el-
evated SCCA2 to SCCA1 mRNA ratio and
the presence of lymph node metastasis, indi-
cating that these two prognostic variables re-
flect different malignant features of the tu-
mors.
Inoculation of tumors with an antisense
SCCA mRNA construct suppressing the ex-
pression of both SCCA1 and SCCA2 has been
shown to suppress tumor growth in vivo.
[Suminami, 2001] This effect has been sug-
gested to be partly explained by the ability
of SCCA1 to inhibit migration of NK-cells.
Tumor cells transduced with SCCA1 cDNA
have also been shown to be more resistant to
induced apoptosis as compared to control cells
in vitro, and also to form larger tumors than
corresponding controls in nude mice. [Sum-
inami, 2000] We observed a relative increase
in SCCA2 expression in relation to SCCA1
in tumors with a poor outcome. The method
used for relative quantification does not, how-
ever, exclude the possibility that the abso-
lute levels of both SCCA1 and SCCA2 were
elevated in these cases. As the number of clini-
cal samples for which follow up data was
available was limited, the power of our sta-
tistical analyses remains fairly weak. Our re-
sults, however, indicate that in addition to
an absolute rise in the expression of the SCCA
genes, also a relative increase in the expres-
sion of SCCA2 could play a functional role in
the pathophysiology of squamous cell carci-
nomas.
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Summary and Conclusions
We have been able to show that highly accu-
rate mRNA quantification can be achieved
by comparing the levels of closely related tran-
scripts to each other. The concept of using a
closely related mRNA transcript as a refer-
ence template for quantification has been
demonstrated in a competitive RT-PCR based
technique. This technique as such is unlikely
to be directly applied as a tool for mRNA
based grading in the future due to the rela-
tively complicated methodology. The concept
of relative quantification of closely related
mRNA:s is however readily applicable to a
real-time PCR setup as well as to other am-
plification- and detection technologies.
We were able to demonstrate the effect of
stochastic sampling variation in amplification
systems at different template concentrations.
These effects are equally present regardless of
quantification technology, but are greatly are
pronounced at low levels of input template
when quantification is done against a refer-
ence template. Below a level of 1000 tem-
plate molecules the stochastic distribution of
target molecules during sampling is a major
source of variation. As the sensitivity of RT-
PCR is sufficient for quantification of mRNA
expression from even single cells, accurate
quantification is possible only for highly ex-
pressed targets. For most gene transcripts, RT-
PCR remains a qualitative technique at the
single cell level.
The relative levels of SCCA1 and SCCA2
mRNA in squamous cell tumors of the head
and neck region was demonstrated to corre-
late with tumor types displaying an aggres-
sive behavior as well as with the recurrence
free survival of the patients. These consistent
but subtle variations in the relative levels of
the SCCA genes were beyond the quantita-
tive accuracy of the most commonly used
techniques for mRNA quantification. As the
number of patient samples with available
follow up data was limited in our study, the
clinical applicability of the SCCA2/SCCA1
mRNA ratio as a molecular marker in head
and neck cancer remains to be verified. For
the time being, measurement of this param-
eter remains a potential target for future
grading techniques for squamous cell carci-
nomas of the head and neck region and pos-
sibly of other sites.
Using a sensitive non-quantitative RT-
PCR assay for SCCA mRNA we were able
to detect occult epithelial cells in the cir-
culation of cervical cancer patients. In an
attempt to use a quantitative method ca-
pable of quantifying down to 40 copies of
mRNA template, that would distinguish
expression from occult epithelial cells from
a possible baseline expression in blood cells,
we could not however reliably detect ma-
lignant cells in the samples. It is likely that
detection of mRNA from malignant cells
in the peripheral circulation is hampered
by stochastic considerations due to low and
variable levels of occult cells in circulation
at a given time point. This phenomenon
equally concerns detection techniques based
on enrichment of malignant cells with im-
munological or gradient centrifugation
techniques. RT-PCR provides a potential
technology to detect and quantify occult
cells at sites where they are enriched over a
period of time, such as lymph nodes, bone
marrow aspirates and possibly also leuka-
pheresis harvests. The use of RT-PCR for
detecting occult cells in peripheral blood
cannot, however, be considered feasible in
a clinical setting.
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